PsychedelicNewsBreaks

TuesdayFeb 01, 2022 11:10 am

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series

Clearmind Medicine (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) a psychedelic drug company, has announced the speaker for the third webinar in its Psychedelics for Alcoholism series. The company has invited addiction specialist and world-renowned author Dr. Gabor Maté to talk on the effects of Alcohol Use Disorder, addition and trauma. The webinar will also include information about Clearmind's patented portfolio as an effective treatment for the disorder. A retired Vancouver physician and a member of the Order of Canada, Maté has written several books with his most recent book —  “The Myth of Normal: Trauma, Illness and Healing in a Toxic Culture” —…

Continue Reading

MondayJan 31, 2022 3:31 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole in a fast-growing sector rife with opportunity. “Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University (‘JHU’) to advance the company’s lead drug candidate MYCO-001 as a smoking cessation treatment… In 2022, Johnson…

Continue Reading

MondayJan 31, 2022 1:49 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event

Clearmind Medicine (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems. The company has announced that, as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté to discuss alcohol use disorder and how Clearmind’s candidate treatment may create a clear path to dealing with trauma. The special virtual event, slated to take place starting at 12 p.m. ET on Feb. 3, 2022, is open and free to all, with registration required. Renowned speaker and bestselling author Dr.…

Continue Reading

ThursdayJan 27, 2022 11:23 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Scheduled Release of Q3 Financial Results, Conference Call

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will report financial results for its third quarter ended Dec. 31, 2021, on Thursday, Feb. 10, 2022. According to the announcement, a conference call will be held on the same day at 8:30 a.m. ET to discuss the results and recent business updates. Cybin’s Chief Executive Officer Doug Drysdale will host the call and, following prepared remarks, Drysdale and other members of the management team will be available to answer questions from participants. Interested parties should visit https://ibn.fm/quTwC to register for…

Continue Reading

MondayJan 24, 2022 12:36 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King's College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to the update, Combat Stress, the leading charity aiding veterans’ mental health in the United Kingdom, will be one of several sites for Mydecine’s upcoming clinical trials. “The team is thrilled to be conducting studies within the veteran population where the help is needed most,” said…

Continue Reading

MondayJan 24, 2022 12:08 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Access of New Medicines, Treatment for Mental Health Conditions

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recently announced its wholly owned ketamine infusion clinic chain, Ketamine Wellness Centers LLC (“KWC”), will open two new clinics in Salt Lake City, Utah, and Reno, Nevada, by February 2022. KWC, at that time, had cumulatively delivered over 60,000 treatments across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington. A recent article reads, “Delic will open 13 ketamine infusion clinics across the country over the next 18 months, adding to the company’s existing portfolio, which comprises of 12 KWC clinics as well as two clinics operated by subsidiary…

Continue Reading

ThursdayJan 20, 2022 9:56 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Unveils Newly Designed Corporate Website

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the launch of its newly designed website. According to the update, the new site conveys the company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. “We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeutics,” said Anthony Durkacz, interim CEO of FSD Pharma. “With some of the greatest minds in…

Continue Reading

WednesdayJan 19, 2022 1:03 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”). The notice was regarding Cybin’s patent application connected to its investigational deuterated psychedelic tryptamine compound, CYB004, for the potential treatment of anxiety disorders. “The receipt of this notice of allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the company’s dedication to the discovery and development of differentiated psychedelic-based…

Continue Reading

WednesdayJan 19, 2022 9:32 am

PsychedelicNewsBreaks – Microdose Psychedelic Insights’ Upcoming Conference to Showcase Top Companies, Newest Opportunities Within Psychedelics Sector

Microdose Psychedelic Insights, the leading guide to the business of psychedelics, will be hosting the upcoming Psychedelic Capital: January 2022 Conference in an entirely virtual format on Jan. 27, 2022, starting at 1:30 p.m. EST. The event will shine the spotlight on some of the top companies, latest IPOs, newest opportunities and deepest industry insights within the psychedelics sector. As part of a bimonthly investor conference series that dives deep into psychedelic medicine investment, the event will introduce attendees to a curated group of CEOs, capital advisors and investment luminaries from around the world. The event will start with a…

Continue Reading

TuesdayJan 18, 2022 2:40 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Releases Results of Harris Survey on Psychedelics as an Alternative Treatment

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that nearly two-thirds (65%) of Americans who suffer from anxiety, depression and PTSD believe that psychedelic medicine, including ketamine, psilocybin and MDMA, should be available to patients with treatment-resistant anxiety, depression or PTSD. The online survey included 953 adults living in the United States who suffer from anxiety, depression or PTSD. Of those surveyed, 63% of those who have used prescription medications for treatment response that, while the medication helped, they still experienced residual feelings of anxiety, depression or…

Continue Reading